Skip to main content

Table 2 Changes from baseline in pulmonary function*

From: One-year treatment with mometasone furoate in chronic obstructive pulmonary disease

  MF-DPI 800 μg QD PM 800(n = 275) MF-DPI 400 μg BID (n = 278) Placebo (n = 256)
Prebronchodilator FEV1, L (pSD)    
   Longitudinal average 0.029 (0.182) 0.041 (0.182) -0.034 (0.182)
   ΔMF-DPI – placebo (95% CI) 0.063 (0.033–0.094) 0.075 (0.044–0.105)  
Postbronchodilator FEV1, L (SD)    
   Longitudinal average 0.050 (0.182) 0.053 (0.183) -0.019 (0.176)
   ΔMF-DPI – placebo (95% CI) 0.069 (0.040–0.098) 0.072 (0.044–0.102)  
Prebronchodilator FEF25%–75%, L/se(pSD)    
   Longitudinal average 0.027 (0.169) 0.037 (0.169) -0.016 (0.169)
   ΔMF-DPI – placebo (95% CI) 0.043 (0.014–0.071) 0.053 (0.024–0.082)  
Postbronchodilator FEF25%–75%, L/s (pSD)    
   Longitudinal average 0.049 (0.185) 0.042 (0.185) 0.02 (0.185)
   ΔMF-DPI – placebo (95% CI) 0.047 (0.015–0.079) 0.040 (0.09–0.072)  
Prebronchodilator FVC, L (pSD)    
   Longitudinal average 0.031 (0.328) 0.045 (0.328) -0.066 (0.328)
   ΔMF-DPI – placebo (95% CI) 0.09 (0.042–0.153) 0.111 (0.056–0.166)  
Postbronchodilator FVC, L (pSD)    
   Longitudinal average 0.066 (0.316) 0.044 (0.316) -0.028 (0.316)
   ΔMF-DPI – placebo (95% CI) 0.094 (0.040–0.148) 0.072 (0.018–0.125)  
  1. BID = twice daily; FEF25%–75% = forced expiratory flow between 25% and 75% of vital capacity; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; MF-DPI = mometasone furoate administered via a dry powder inhaler; pSD = pooled standard deviation.
  2. *This table shows spirometry results in subjects for whom both pre- and postbronchodilator data were available.
  3. P < 0.001 vs placebo
  4. P ≤ 0.009 vs placebo